Drug policy

• Like you know transitioning to housing, even help with you know finding work and that, but […] none of those promises were met.
• Like you know transitioning to housing, even help with you know finding work and that, but […] none of those promises were met.
• Getting this kind of pre- and post-release support can drastically reduce the risk of the person re-offending.

System failure

In 2019‑20, 46% of prisoners released in 2017-18 had returned to prison within two years. People who inject drugs are disproportionately more likely to return to prison. This suggests a systemic failure; something is going wrong in the way we provide services to this group of people. For this analysis, “service providers” include actors such as:
• For example, when Jidah got out of prison, he needed crucial medication for his opioid dependence.
• And I was that frustrated that it caused me to relapse and get back on the heroin.
• And I was that frustrated that it caused me to relapse and get back on the heroin.
• Khish told us he was given some support in getting set up for post-prison life but the help was limited.

Trust is key

• Being able to trust a service provider is crucial and can enable a smoother transition to community.
• Ben, however, didn’t find his parole officer “useful”, saying:
  They’re not really there to help you.
• They’re there to watch over you, but they say they can help.

Getting the right support can be ‘life-changing’

• Under this new philosophy, Maine’s prisons focus on rehabilitation and growing respect between correctional officers and people who are incarcerated.
• It can help reduce the chances the prison system is simply reproducing disadvantage and replicating the problems it is ostensibly supposed to solve.
• If you or someone you know needs help with exiting prison, you can find a list of resources here.
• The NSW Users and AIDS Association (NUAA) PeerLine on 1800 644 413 may also be helpful.

• MedPharm Research, a wholly owned subsidiary of MedPharm Holdings, a leading medical cannabis manufacturer, R&D laboratory, and compounding facility, announces that they have been approved for a Drug Enforcement Administration (DEA) Schedule I Researcher License.
• The DEA makes the final determination on approving applications for research using schedule I substances and drugs.
• Its been a long road to getting a federally approved license, Albert Gutierrez, CEO of MedPharm Research, says.
• The DEA license enables MedPharm Research to isolate and evaluate the activity of phytocannabinoids on different brain cells (such as neuron, astrocytes, microglia).

• \xe2\x80\x9cAs we continue building out the Fund\xe2\x80\x99s media strategy, we feel lucky to have Global Trac\xe2\x80\x99s world-class expertise behind us; the Psychedelic Spotlight platform in particular has been a fantastic resource to leverage.
• Forward-looking statements are not a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved.
• We support a harm reduction approach for the purpose of education and promoting individual and public safety.
• If you are choosing to use psychedelic substances, please do so responsibly.\n'

• "Latin America is the fastest-growing regional ecommerce market in the world," says A.J.
• "It's possible to market there the way you would anywhere else.
• As an example of the need to know how, Hernandez cites the supposed prohibition on importing cosmetics into Mexico.
• Instead of applying the previously used simplified carrier clearance, MEX now requires a much more laborious and costly customs entry procedure.